The FDA cleared Eli Lilly and Co.'s Portrazza (necitumumab) in combination with two forms of chemotherapy to treat patients with advanced (metastatic) squamous non-small-cell lung cancer (NSCLC) who have not previously received medication for their later-stage disease.